Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

doi:10.1016/j.jhep.2011.03.029

CNU IR > College of Smart Living > Dept. of Senior Service and Health Management > Periodical Articles > Item 310902800/27727

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/27727

Title:	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
Authors:	Huang, Chung-Feng Huang, Jee-Fu Yang, Jeng-Fu Hsieh, Ming-Yen Lin, Zu-Yau Chen, Shinn-Cherng Wang, Liang-Yen Juo, Suh-Hang Hank Chen, Ku-Chung Chuang, Wan-Long Kuo, Hsing-Tao Dai, Chia-Yen Yu, Ming-Lung
Contributors:	老人服務事業管理系
Keywords:	Hcv Il-28B Tailored Regimen Treatment
Date:	2012
Issue Date:	2014-03-24 15:22:57 (UTC+8)
Publisher:	Elsevier Science Bv
Abstract:	Background & Aims: A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen.Methods: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin.Results: Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p <0.001) and SVR (64.7% vs. 25.6%, p <0.001) rates, and lower relapse rate (28.0% vs. 54.5%, p = 0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/95% confidence intervals [OR/CI]: 6.24/2.34-16.63), followed by lower viral loads (OR/CI: 5.29/2.81-9.93) and age (OR/CI: 0.94/0.919.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22-53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18-9.65), lower viral loads (OR/CI: 2.23/1.00-4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06-1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%.Conclusions: Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Relation:	Journal of Hepatology v.56 n.1 pp.34-40
Appears in Collections:	[Dept. of Senior Service and Health Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	2113	View/Open

Loading...